Imunon, Inc. (NASDAQ:IMNN) Short Interest Update

Imunon, Inc. (NASDAQ:IMNN) saw a large increase in short interest in November. As of November 30th, there was short interest totalling 738,600 shares, an increase of 5.2% from the November 15th total of 702,000 shares. Currently, 5.4% of the company’s stock are sold short. Based on an average trading volume of 207,400 shares, the short-interest ratio is presently 3.6 days.

Wall Street Analyst Weigh In

Several analysts have issued reports on IMNN shares. EF Hutton Acquisition Co. I upgraded Imunon to a “strong-buy” rating in a research note on Monday, September 23rd. D. Boral Capital restated a “buy” rating and set a $29.00 price objective on shares of Imunon in a research note on Tuesday, December 10th. Finally, HC Wainwright reiterated a “buy” rating and set a $12.00 target price on shares of Imunon in a research note on Wednesday, December 11th.

Imunon Stock Up 3.2 %

Shares of NASDAQ IMNN opened at $0.87 on Wednesday. The stock has a market capitalization of $12.58 million, a P/E ratio of -0.46 and a beta of 2.12. The firm’s 50-day moving average price is $0.88 and its two-hundred day moving average price is $1.08. Imunon has a 52-week low of $0.48 and a 52-week high of $3.65.

Imunon Company Profile

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development.